GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Days Sales Outstanding

Affimed NV (Affimed NV) Days Sales Outstanding : 853.59 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Days Sales Outstanding?

Affimed NV's average Accounts Receivable for the three months ended in Dec. 2023 was $4.21 Mil. Affimed NV's Revenue for the three months ended in Dec. 2023 was $0.45 Mil. Hence, Affimed NV's Days Sales Outstanding for the three months ended in Dec. 2023 was 853.59.

The historical rank and industry rank for Affimed NV's Days Sales Outstanding or its related term are showing as below:

AFMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.8   Med: 41.15   Max: 282.53
Current: 129.87

During the past 12 years, Affimed NV's highest Days Sales Outstanding was 282.53. The lowest was 19.80. And the median was 41.15.

AFMD's Days Sales Outstanding is ranked worse than
74.94% of 890 companies
in the Biotechnology industry
Industry Median: 71.92 vs AFMD: 129.87

Affimed NV's Days Sales Outstanding increased from Dec. 2022 (17.49) to Dec. 2023 (853.59).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.


Affimed NV Days Sales Outstanding Historical Data

The historical data trend for Affimed NV's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Days Sales Outstanding Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.13 24.41 33.61 34.54 175.26

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.49 47.65 136.94 107.72 853.59

Competitive Comparison of Affimed NV's Days Sales Outstanding

For the Biotechnology subindustry, Affimed NV's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affimed NV's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Affimed NV's Days Sales Outstanding falls into.



Affimed NV Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Affimed NV's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.857 + 5.809) / 2 ) / 9.024*365
=4.333 / 9.024*365
=175.26

Affimed NV's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.61 + 5.809) / 2 ) / 0.45*365 / 4
=4.2095 / 0.45*365 / 4
=853.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affimed NV  (NAS:AFMD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Affimed NV Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Affimed NV's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (Affimed NV) Business Description

Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (Affimed NV) Headlines

From GuruFocus

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

By Stock market mentor Stock market mentor 01-09-2023

Affimed Announces Annual General Meeting of Shareholders

By sperokesalga sperokesalga 05-22-2023